Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancerNicolò Matteo Luca Battisti, Alistair Ring, Kalaprapa Asavisanu et al.|Breast Cancer Research and Treatment|2021Cited by 74
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyCarlo G. Tocchetti, Teresa López‐Fernández, Alexander R. Lyon et al.|European Journal of Heart Failure|2024Cited by 64
Cardiovascular Considerations Before Cancer TherapyZahra Raisi‐Estabragh, Charlotte Manisty, A. Murphy et al.|JACC CardioOncology|2024Cited by 53